Abstract

HIV establishes a persistent infection in heterogeneous cell reservoirs, which can be maintained by different mechanisms including cellular proliferation, and represent the main obstacle to curing the infection. The expression of the Fcγ receptor CD32 has been identified as a marker of the active cell reservoirs in people on antiretroviral therapy, but if its expression has any role in conferring advantage for viral persistence is unknown. Here, we report that HIV-infected cells expressing CD32 have reduced susceptibility to natural killer (NK) antibody-dependent cell cytotoxicity (ADCC) by a mechanism compatible with the suboptimal binding of HIV-specific antibodies. Infected CD32 cells have increased proliferative capacity in the presence of immune complexes, and are more resistant to strategies directed to potentiate NK function. Remarkably, reactivation of the latent reservoir from antiretroviral-treated people living with HIV increases the pool of infected CD32 cells, which are largely resistant to the ADCC immune mechanism. Thus, we report the existence of reservoir cells that evade part of the NK immune response through the expression of CD32.

Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files. Source data are provided with this paper.

Article and author information

Author details

  1. Antonio Astorga-Gamaza

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  2. Judith Grau-Expósito

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Joaquín Burgos

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  4. Jordi Navarro

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7187-0367
  5. Adrià Curran

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  6. Bibiana Planas

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  7. Paula Suanzes

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6871-0098
  8. Vicenç Falcó

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Meritxell Genescà

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  10. Maria Buzon

    Infectious Disease Department, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
    For correspondence
    mariajose.buzon@vhir.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4427-9413

Funding

Spanish National Plan for Scientific and Technical Research and Innovation (SAF2015-67334-R)

  • Maria Buzon

Spanish National Plan for Scientific and Technical Research and Innovation (RTI2018-101082-B)

  • Maria Buzon

Fundació La Marató TV3 (201805-10FMTV3)

  • Maria Buzon

Fundació La Marató TV3 (201814-10FMTV3)

  • Meritxell Genescà

Spanish Health Institute Carlos III (CP17/00179)

  • Maria Buzon

Spanish National Plan for Scientific and Technical Research and Innovation (BES-2016-076382)

  • Antonio Astorga-Gamaza

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: This study involves human samples. PBMCs from PLWH were obtained from the HIV unit of the Hospital Universitari Vall d'Hebron in Barcelona, Spain. Study protocols were approved by the corresponding Ethical Committees (Institutional Review Board numbers PR(AG)270/2015 and PR(AG)39/2016). PBMCs from healthy donors were obtained from the Blood and Tissue Bank, Barcelona, Spain. All subjects recruited to this study were adults who provided written informed consent. Samples were completely anonymous and untraceable and were prospectively collected and cryopreserved in the Biobank (register number C.0003590).

Copyright

© 2022, Astorga-Gamaza et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,042
    views
  • 317
    downloads
  • 17
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Antonio Astorga-Gamaza
  2. Judith Grau-Expósito
  3. Joaquín Burgos
  4. Jordi Navarro
  5. Adrià Curran
  6. Bibiana Planas
  7. Paula Suanzes
  8. Vicenç Falcó
  9. Meritxell Genescà
  10. Maria Buzon
(2022)
Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response
eLife 11:e78294.
https://doi.org/10.7554/eLife.78294

Share this article

https://doi.org/10.7554/eLife.78294

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Mai Nguyen, Elda Bauda ... Cecile Morlot
    Research Article

    Teichoic acids (TA) are linear phospho-saccharidic polymers and important constituents of the cell envelope of Gram-positive bacteria, either bound to the peptidoglycan as wall teichoic acids (WTA) or to the membrane as lipoteichoic acids (LTA). The composition of TA varies greatly but the presence of both WTA and LTA is highly conserved, hinting at an underlying fundamental function that is distinct from their specific roles in diverse organisms. We report the observation of a periplasmic space in Streptococcus pneumoniae by cryo-electron microscopy of vitreous sections. The thickness and appearance of this region change upon deletion of genes involved in the attachment of TA, supporting their role in the maintenance of a periplasmic space in Gram-positive bacteria as a possible universal function. Consequences of these mutations were further examined by super-resolved microscopy, following metabolic labeling and fluorophore coupling by click chemistry. This novel labeling method also enabled in-gel analysis of cell fractions. With this approach, we were able to titrate the actual amount of TA per cell and to determine the ratio of WTA to LTA. In addition, we followed the change of TA length during growth phases, and discovered that a mutant devoid of LTA accumulates the membrane-bound polymerized TA precursor.

    1. Microbiology and Infectious Disease
    Ziyu Wen, Pingchao Li ... Caijun Sun
    Research Article

    The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein found that ICP34.5 can act as an antagonistic factor for the reactivation of HIV latency by herpes simplex virus type I (HSV-1), and thus recombinant HSV-1 with ICP34.5 deletion could more effectively reactivate HIV latency than its wild-type counterpart. Mechanistically, HSV-ΔICP34.5 promoted the phosphorylation of HSF1 by decreasing the recruitment of protein phosphatase 1 (PP1α), thus effectively binding to the HIV LTR to reactivate the latent reservoirs. In addition, HSV-ΔICP34.5 enhanced the phosphorylation of IKKα/β through the degradation of IκBα, leading to p65 accumulation in the nucleus to elicit NF-κB pathway-dependent reactivation of HIV latency. Then, we constructed the recombinant HSV-ΔICP34.5 expressing simian immunodeficiency virus (SIV) env, gag, or the fusion antigen sPD1-SIVgag as a therapeutic vaccine, aiming to achieve a functional cure by simultaneously reactivating viral latency and eliciting antigen-specific immune responses. Results showed that these constructs effectively elicited SIV-specific immune responses, reactivated SIV latency, and delayed viral rebound after the interruption of antiretroviral therapy (ART) in chronically SIV-infected rhesus macaques. Collectively, these findings provide insights into the rational design of HSV-vectored therapeutic strategies for pursuing an HIV functional cure.